1999
DOI: 10.1111/j.1349-7006.1999.tb00750.x
|View full text |Cite
|
Sign up to set email alerts
|

Expression of Fibronectin Isoforms in Human Breast Tissue: Production of Extra Domain A+/Extra Domain B+ by Cancer Cells and Extra Domain A+ by Stromal Cells

Abstract: The expression of fibronectin (FN) isoforms including extra domain A (EDA) and extra domain B (EDB) segments, was investigated in 36 invasiveMany recent studies have demonstrated that FN is upregulated in cancer tissues, with reappearance of alternatively spliced isoforms. [6][7][8][9] In breast cancers, immunohistochemical studies using specific monoclonal antibodies have demonstrated that FN isoforms, including EDA (EDA + FN) and EDB (EDB + FN) can be detected in cancer stroma. [10][11][12] In contrast, it h… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
25
0

Year Published

2003
2003
2022
2022

Publication Types

Select...
5
4
1

Relationship

1
9

Authors

Journals

citations
Cited by 43 publications
(28 citation statements)
references
References 16 publications
1
25
0
Order By: Relevance
“…Furthermore, whereas there are reports about EDA expression in tumor cells and in solid tumors at the mRNA level (see, e.g., refs. 44,45), at the level of isolated protein (46) and at the immunohistochemical level (21, 47-50), we could not find any report of EDA expression in the neovasculature of liver and lung metastases. The work presented in this article strongly encourages the clinical development of anti-EDA antibody derivatives, in full analogy to anti-EDB antibodies.…”
Section: Cancer Researchmentioning
confidence: 54%
“…Furthermore, whereas there are reports about EDA expression in tumor cells and in solid tumors at the mRNA level (see, e.g., refs. 44,45), at the level of isolated protein (46) and at the immunohistochemical level (21, 47-50), we could not find any report of EDA expression in the neovasculature of liver and lung metastases. The work presented in this article strongly encourages the clinical development of anti-EDA antibody derivatives, in full analogy to anti-EDB antibodies.…”
Section: Cancer Researchmentioning
confidence: 54%
“…These documented characteristics of breast-derived CAF are thoroughly reviewed by Kunz-Schughart and Knuechel [1,2], and include an increased expression of several growth factors [3,34], of ECM molecules [35-37], and of proteases and protease inhibitors involved in modulating the ECM [5,6]. Many of these differences in the expression profile of CAF in comparison with NAF have the potential to enhance the development, growth and progression of breast carcinoma [1].…”
Section: Discussionmentioning
confidence: 99%
“…CAFs differ from NMFs also in their increased expression of growth factors [16,17], and different profiles of ECM molecule synthesis [18-20] and ECM-altering proteases and protease inhibitors [21,22]. The role played by fibroblasts in the development or progression of cancer is not yet fully understood, and the use of physiologically relevant co-culture models using fibroblasts from normal and cancer stroma may provide a tool for the analysis of the effect of fibroblasts.…”
Section: Introductionmentioning
confidence: 99%